SFDA Approves Marketing Authorization for Diagnostic Medical Devices to Measure Antipsychotic Drug Levels in Blood

The Saudi Food and Drug Authority (SFDA) has approved the marketing authorization for in-vitro diagnostic medical devices that utilize biotechnology to accurately detect concentrations of antipsychotic medications in the blood. These include Quetiapine, Olanzapine, Aripiprazole, Clozapine, and Risperidone.

Regulatory Approval Based on Comprehensive Scientific Evaluation

The Kingdom of Saudi Arabia is among the first countries globally to grant approval for this type of device. This decision came after the SFDA conducted a comprehensive scientific evaluation, meeting all requirements. This evaluation included reviewing technical and clinical documentation, as well as clinical trial reports, all supervised by specialized experts to ensure the devices' safety and effectiveness.

An Accurate Tool to Enhance Quality of Care

These devices contribute to supporting treatment plans for conditions such as schizophrenia, manic episodes, and depression associated with bipolar disorder. They empower doctors to accurately measure drug levels, monitor patient adherence to treatment, and adjust dosages when needed. This helps achieve the best possible therapeutic balance between effectiveness and minimized side effects.

Adopting Nanotechnology for Concentration Measurement

These devices rely on nanoparticle agglutination assay technology, which uses nanoparticles that bind to drug-specific antibodies. Their accumulation is then measured via a spectrophotometer, allowing for an accurate reading of the drug level in the blood and enhancing the chances of successful treatment with precision and safety.

Extension of Health Transformation Efforts and Biotechnology Adoption

This step aligns with the SFDA's commitment to supporting the National Biotechnology Strategy and is part of the objectives of the Health Sector Transformation Program, a key initiative under Saudi Vision 2030. It reflects the SFDA's role in enabling innovation and providing a flexible regulatory environment that supports reliable healthcare solutions in line with global best practices.